Faculty profile

Anne Marinier

ResearcherChemistryUniversité de Montréal

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université de Montréal directory, so their courses may be missing. Find their university profile.

Anne Marinier

Researcher

Chemistry

Health Sciences

Université de Montréal

Montreal, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
6 publications in the last five years, latest in 2026.
Principal investigator on 2 research grants (2 CIHR), most recently in 2024.
Supervisor on 1 trainee award (1 CIHR), most recently in 2012.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Biased Signaling Breast Cancer Cancer Therapeutics Cell-Based Screens Dna-Encoded Chemical Libraries (Decl)Drug Discovery Early Hits Identification G-Protein Coupled Receptors (Gpcrs)

Latest papers

A Chemical-Genetic Interaction Matrix Reveals Drug Mechanism and Genetic Architecture.
bioRxiv : the preprint server for biology · 2026
DDB1 engagement defines the selectivity of S656 analogs for cyclin K degradation over CDK inhibition.
EMBO reports · 2025
A Novel Confocal Scanning Protein-Protein Interaction Assay (PPI-CONA) Reveals Exceptional Selectivity and Specificity of CC0651, a Small Molecule Binding Enhancer of the Weak Interaction between the E2 Ubiquitin-Conjugating Enzyme CDC34A and Ubiquitin.
Bioconjugate chemistry · 2024

All 16 publications

Latest funding

Distilled-DEL: A novel DNA-encoded drug discovery platform enabling biological evaluation of cellular targets on live cells.
CIHR · 2024 · Nominated PI
$100,000
Mechanisms of action of antiestrogens in breast cancer: roles of ubiquitin-like modifications in transcriptional inactivation of Estrogen Receptor alpha.
CIHR · 2023 · Co-investigator
$841,500
Cross-disciplinary Acuity Training Program in Intelligent and Responsible Drug Discovery
NSERC · 2023 · Co-investigator
$463,000

All 13 grants and awards

16 publications.

A Chemical-Genetic Interaction Matrix Reveals Drug Mechanism and Genetic Architecture.

Coulombe-Huntington J, Bertomeu T, Huard C, Chatr-Aryamontri A, St-Cyr DJ, Sánchez-Osuna M, Papadopoli D, Normandin K, Paydar M, McLaughlan S, St-Denis C, Zhang L, Say H, Palou R, Stark C, Breitkreutz BJ, van der Sloot AM, Manohar S, Lavoie H, Borden KLB, Raught B, D'Amours D, Sicheri F, Verreault A, Mader S, Meloche S, Therrien M, Thibault P, Wilhelm B, Dirks PB, Aitchison JD, Patton E, King RW, Roux PP, Sauvageau G, Hoang T, Marinier A, Harrington L, Kwok B, Archambault V, Topisirovic I, Tyers M

bioRxiv : the preprint server for biology2026

DOI: 10.64898/2026.01.28.701823 PMID: 41659671

DDB1 engagement defines the selectivity of S656 analogs for cyclin K degradation over CDK inhibition.

Moison C, Mendoza-Sanchez R, Gracias D, Schuetz DA, Spinella JF, Girard S, Thavonekham B, Chagraoui J, Durand A, Fortier S, MacRae T, Bonneil E, Rose Y, Mayotte N, Boivin I, Thibault P, Hébert J, Ruel R, Marinier A, Sauvageau G

EMBO reports2025

DOI: 10.1038/s44319-025-00448-y PMID: 40295725

A Novel Confocal Scanning Protein-Protein Interaction Assay (PPI-CONA) Reveals Exceptional Selectivity and Specificity of CC0651, a Small Molecule Binding Enhancer of the Weak Interaction between the E2 Ubiquitin-Conjugating Enzyme CDC34A and Ubiquitin.

Koszela J, Pham NT, Shave S, St-Cyr D, Ceccarelli DF, Orlicky S, Marinier A, Sicheri F, Tyers M, Auer M

Bioconjugate chemistry2024

DOI: 10.1021/acs.bioconjchem.4c00345 PMID: 39167708

Medicinal Chemistry and NMR Driven Discovery of Novel UDP-glucuronosyltransferase 1A Inhibitors That Overcome Therapeutic Resistance in Cells.

Osborne MJ, Sulekha A, Culjkovic-Kraljacic B, Gasiorek J, Ruediger E, Jolicouer E, Marinier A, Assouline S, Borden KLB

Journal of molecular biology2024

DOI: 10.1016/j.jmb.2023.168378 PMID: 38043731

Discovery of Benzodiazepine-Based Inhibitors of the E2 Enzyme UBCH10 from a Cell-Based p21 Degradation Screen.

Pelletier B, Duhamel S, Tambutet G, Jarvis S, Cléroux P, David M, Tanguay PL, Voisin L, James C, Lavoie R, Gareau Y, Flynn-Robitaille J, Lorca T, Ruel R, Marinier A, Meloche S

ACS chemical biology2023

DOI: 10.1021/acschembio.2c00909 PMID: 37097827

Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia.

Baran N, Lodi A, Dhungana Y, Herbrich S, Collins M, Sweeney S, Pandey R, Skwarska A, Patel S, Tremblay M, Kuruvilla VM, Cavazos A, Kaplan M, Warmoes MO, Veiga DT, Furudate K, Rojas-Sutterin S, Haman A, Gareau Y, Marinier A, Ma H, Harutyunyan K, Daher M, Garcia LM, Al-Atrash G, Piya S, Ruvolo V, Yang W, Shanmugavelandy SS, Feng N, Gay J, Du D, Yang JJ, Hoff FW, Kaminski M, Tomczak K, Eric Davis R, Herranz D, Ferrando A, Jabbour EJ, Emilia Di Francesco M, Teachey DT, Horton TM, Kornblau S, Rezvani K, Sauvageau G, Gagea M, Andreeff M, Takahashi K, Marszalek JR, Lorenzi PL, Yu J, Tiziani S, Hoang T, Konopleva M

Nature communications2022

DOI: 10.1038/s41467-022-30396-3 PMID: 35589701

Identification and optimization of molecular glue compounds that inhibit a noncovalent E2 enzyme-ubiquitin complex.

St-Cyr D, Ceccarelli DF, Orlicky S, van der Sloot AM, Tang X, Kelso S, Moore S, James C, Posternak G, Coulombe-Huntington J, Bertomeu T, Marinier A, Sicheri F, Tyers M

Science advances2021

DOI: 10.1126/sciadv.abi5797 PMID: 34705497

UM171 Preserves Epigenetic Marks that Are Reduced in Ex Vivo Culture of Human HSCs via Potentiation of the CLR3-KBTBD4 Complex.

Chagraoui J, Girard S, Spinella JF, Simon L, Bonneil E, Mayotte N, MacRae T, Coulombe-Huntington J, Bertomeu T, Moison C, Tomellini E, Thibault P, Tyers M, Marinier A, Sauvageau G

Cell stem cell2021

DOI: 10.1016/j.stem.2020.12.002 PMID: 33417871

Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.

Cohen S, Roy J, Lachance S, Delisle JS, Marinier A, Busque L, Roy DC, Barabé F, Ahmad I, Bambace N, Bernard L, Kiss T, Bouchard P, Caudrelier P, Landais S, Larochelle F, Chagraoui J, Lehnertz B, Corneau S, Tomellini E, van Kampen JJA, Cornelissen JJ, Dumont-Lagacé M, Tanguay M, Li Q, Lemieux S, Zandstra PW, Sauvageau G

The Lancet. Haematology2020

DOI: 10.1016/s2352-3026(19)30202-9 PMID: 31704264

Structure-Based Design of Dimeric Bisbenzimidazole Inhibitors to an Emergent Trimethoprim-Resistant Type II Dihydrofolate Reductase Guides the Design of Monomeric Analogues.

Toulouse JL, Yachnin BJ, Ruediger EH, Deon D, Gagnon M, Saint-Jacques K, Ebert MCCJC, Forge D, Bastien D, Colin DY, Vanden Eynde JJ, Marinier A, Berghuis AM, Pelletier JN

ACS omega2019

DOI: 10.1021/acsomega.9b00640 PMID: 31460098

Distilled-DEL: A novel DNA-encoded drug discovery platform enabling biological evaluation of cellular targets on live cells.

Nominated PICIHR2024Project Grant - PA: Pandemic Preparedness and Health Emergencies Research

Principal investigators: Marinier, Anne

Keywords: Biased Signaling; Breast Cancer; Cancer Therapeutics; Cell-Based Screens; Dna-Encoded Chemical Libraries (Decl); Drug Discovery; Early Hits Identification; G-Protein Coupled Receptors (Gpcrs); Stem Cell Epigenetics; Target Identification And Active Site Mapping

$100,000

Mechanisms of action of antiestrogens in breast cancer: roles of ubiquitin-like modifications in transcriptional inactivation of Estrogen Receptor alpha.

Co-investigatorCIHR2023Project Grant

Principal investigators: Mader, Sylvie N

Keywords: Antiestrogens; Breast Cancer; Chromatin; Cofactors; Drug Design; Estrogen Receptor; Proteomics; Sumoylation; Transcription; Ubiquitination

$841,500

Cross-disciplinary Acuity Training Program in Intelligent and Responsible Drug Discovery

Co-investigatorNSERC2023Collaborative Research and Training Experience

Principal investigators: SARRET, Philippe P

Keywords: advanced device technologies; artificial intelligence; biological targets; biosensors; computing science; drug discovery; imaging; medicinal chemistry

$463,000

Development and preclinical validation of first-in-class dual inhibitors of the atypical MAP kinases ERK3 and ERK4

Co-investigatorCIHR2022Project Grant

Principal investigators: Meloche, Sylvain

Keywords: Cadd; Chemical Biology; Chemical Screens; Drug Development; Erk3/Erk4; Hit-To-Lead Chemistry; Map Kinases; Pharmacology; Preclinical Evaluation; Signal Transduction

$956,250

Mechanisms of action of antiestrogens in breast cancer: roles of Ubi-like modifications in transcriptional inactivation of Estrogen Receptor alpha.

Co-investigatorCIHR2022Project Grant - PA: Breast Cancer Research

Principal investigators: Mader, Sylvie N

Keywords: Antiestrogens; Breast Cancer; Chromatin; Cofactors; Drug Design; Estrogen Receptor; Proteomics; Sumoylation; Transcription; Ubiquitination

$100,000

Development and preclinical validation of first-in-class dual inhibitors of the atypical MAP kinases ERK3 and ERK4

Co-investigatorCIHR2021Project Grant - PA: Breast Cancer Research

Principal investigators: Meloche, Sylvain

Keywords: Chemical Biology; Drug Development; Erk3/Erk4; Hit-To-Lead Chemistry; Map Kinases; Pharmacology; Preclinical Evaluation; Signal Transduction; Structural Biology; Synthetic Lethality

$100,000

Recruitment of SUMO E3 ligases as a new paradigm for transcription factor inactivation

Co-investigatorSSHRC2020New Frontiers in Research Fund - Exploration

Principal investigators: Mader, Sylvie

$250,000

RAS-MAPK signal transduction in normal and cancer cells

Co-investigatorCIHR2017Foundation Grant

Principal investigators: Therrien, Marc

Keywords: Signal Transduction

$3,273,064

Development of small molecule modulators of Ras signaling

Nominated PICIHR2016Project Grant

Principal investigators: Marinier, Anne

Keywords: Computer-Assisted Drug Design; Macrocyclic Peptidomimetics; Protein-Protein Interactions; Ras Signaling; Ras-Erk Pathway; Ras-Raf Interaction; Small Molecule Inhibitors

$860,625

Examining chemical modulation of kinesin-13 activities: From mechanism to validation

Co-investigatorCIHR2016Project Grant

Principal investigators: Kwok, Benjamin H

Keywords: Biochemistry; Cancer; Cell Biology; Chemical Biology; Drug Development; High-Throughput Screen; Kinesin Motor Proteins; Live Cell Imaging; Microscopy; Microtubules

$845,325

From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.

Something wrong or missing on this profile? Suggest a correction

Anne Marinier

Research

Latest papers

Latest funding

A Chemical-Genetic Interaction Matrix Reveals Drug Mechanism and Genetic Architecture.

DDB1 engagement defines the selectivity of S656 analogs for cyclin K degradation over CDK inhibition.

A Novel Confocal Scanning Protein-Protein Interaction Assay (PPI-CONA) Reveals Exceptional Selectivity and Specificity of CC0651, a Small Molecule Binding Enhancer of the Weak Interaction between the E2 Ubiquitin-Conjugating Enzyme CDC34A and Ubiquitin.

Medicinal Chemistry and NMR Driven Discovery of Novel UDP-glucuronosyltransferase 1A Inhibitors That Overcome Therapeutic Resistance in Cells.

Discovery of Benzodiazepine-Based Inhibitors of the E2 Enzyme UBCH10 from a Cell-Based p21 Degradation Screen.

Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia.

Identification and optimization of molecular glue compounds that inhibit a noncovalent E2 enzyme-ubiquitin complex.

UM171 Preserves Epigenetic Marks that Are Reduced in Ex Vivo Culture of Human HSCs via Potentiation of the CLR3-KBTBD4 Complex.

Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.

Structure-Based Design of Dimeric Bisbenzimidazole Inhibitors to an Emergent Trimethoprim-Resistant Type II Dihydrofolate Reductase Guides the Design of Monomeric Analogues.

Cross-disciplinary Acuity Training Program in Intelligent and Responsible Drug Discovery

Recruitment of SUMO E3 ligases as a new paradigm for transcription factor inactivation

Frequent collaborators

Guy Sauvageau

Frank Sicheri

Sylvain Meloche

Pierre Thibault

Trang Hoang

Denis-Claude Roy

Sandra Cohen

Damien D'Amours

Ivan Topisirovic

Vincent Archambault

Brian Raught

Bhushan Nagar

Sachdev Sidhu

Lambert Busque

Jean Roy

Ivan Topisirovic

Marc Therrien

Sylvie Mader

Alain Verreault

Sylvie Mader